Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.  
  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in the pipeline would inhibit production of a protein that may interfere with the effectiveness of chemotherapy.  
  • The 5-year survival rate for cancer has gone up 40 percent in the last 40 years.  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers.…  
  • According to the Pharmaceutical Research and Manufacturers of America, researchers are currently working on 646 medicines for cancer. All are either in clinical trials or under FDA review. …